The prevalence of HRD was higher among TNBC (60%) and tumors with TP53 PVs (71%), which is in line with results obtained in other studies evaluating the prevalence of HRD with a RAD51-based HRD test on diagnostic TNBC tumor samples [21, 33, 38]. This evidence concerns the gene TP53 and neoplasm.